

James Bickford (N.Y. Bar No. 5163498)
United States Department of Justice
Civil Division, Federal Programs Branch
1100 L Street, NW
Washington, DC 20530
James.Bickford@usdoj.gov
Telephone: (202) 305-7632
Attorney for Defendant

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF WASHINGTON**

JEREMY OLSEN,)	
)	
Plaintiff,)	DEFENDANT’S CROSS-MOTION
)	FOR SUMMARY JUDGMENT
v.)	AND OPPOSITION TO
)	PLAINTIFF’S MOTION FOR
)	SUMMARY JUDGMENT
ALEX M. AZAR II, in his official)	
capacity as Secretary of Health and)	Case No. 2:20-cv-374 (SMJ)
Human Services,)	
)	Pl.’s Motion: Jan. 7, 2021
Defendant.)	Def.’s Cross-Motion: Jan. 28, 2021
)	
)	Without Oral Argument

1 Jeremy Olsen claims a right to reimbursement by Medicare for continuous
2 glucose monitor supplies. Acting for the Secretary of Health and Human Services,
3 the Medicare Appeals Council denied coverage in accordance with CMS Ruling
4 1682-R. Mr. Olsen now seeks judicial review. But the Secretary’s decision that
5 continuous glucose monitors accurate enough to replace a blood glucose monitor
6 would be covered by Medicare, while less accurate devices would not, was neither

1 arbitrary nor unlawful. Mr. Olsen’s motion for summary judgment should
2 therefore be denied, and the Secretary’s cross-motion granted.

3 **BACKGROUND**

4 **A. Medicare Part B and CMS Ruling 1682-R**

5 Medicare is a federal health insurance program for the elderly and disabled,
6 *see* 42 U.S.C. § 1395 *et seq.*, which is administered on behalf of the Secretary of
7 Health and Human Services by the Centers for Medicare & Medicaid Services
8 (CMS). Part A of the Medicare statute “covers medical services furnished by
9 hospitals and other institutional care providers.” *Ne. Hosp. Corp. v. Sebelius*, 657
10 F.3d 1, 2 (D.C. Cir. 2011) (citing 42 U.S.C. §§ 1395c to 1395i-5). Medicare Part B
11 “is an optional supplemental insurance program that pays for medical items and
12 services not covered by Part A, including outpatient physician services” and
13 “durable medical equipment,” among other things. *Id.* (citing 42 U.S.C. §§ 1395j
14 to 1395w-4).

15 The statutory definition of durable medical equipment (DME), codified at 42
16 U.S.C. § 1395x(n), “includes iron lungs, oxygen tents, hospital beds, and
17 wheelchairs . . . used in the patient’s home,” as well as “blood-testing strips and
18 blood glucose monitors for individuals with diabetes” among other specified items.
19 A regulation elaborates that durable medical equipment is “equipment[] furnished
20 by a supplier or a home health agency that meets the following conditions:

1 (1) Can withstand repeated use.

2 (2) Effective with respect to items classified as DME after January 1, 2012,
3 has an expected life of at least 3 years.

4 (3) Is primarily and customarily used to serve a medical purpose.

5 (4) Generally is not useful to an individual in the absence of an illness or
6 injury.

7 (5) Is appropriate for use in the home.

8 42 C.F.R. § 414.202. Such equipment is only covered by Medicare Part B if it is
9 “reasonable and necessary for the diagnosis or treatment” of a beneficiary’s
10 “illness or injury.” 42 U.S.C. § 1395y(a)(1)(A). And the Secretary has the
11 authority to “establish and implement quality standards for suppliers of items and
12 services” covered by Medicare Part B. *Id.* § 1395m(a)(20).

13 In 2017, the Secretary issued a CMS Ruling—a “statement of policy or
14 interpretation” that is “binding on all CMS components,” 42 C.F.R. § 401.108; *see*
15 *id.* § 405.1063(b)—on the subject of Part B coverage for continuous glucose
16 monitors. CMS Ruling 1682-R (Jan 12, 2017), *available at* [https://www.cms.gov/](https://www.cms.gov/Regulations-and-Guidance/Guidance/Rulings/Downloads/CMS1682R.pdf)
17 [Regulations-and-Guidance/Guidance/Rulings/Downloads/CMS1682R.pdf](https://www.cms.gov/Regulations-and-Guidance/Guidance/Rulings/Downloads/CMS1682R.pdf). CGMs
18 measure glucose levels in the interstitial fluid between patients’ cells, not in their
19 blood. *Id.* at 6. The CMS Ruling said that some continuous glucose monitors were
20 accurate enough to replace a blood glucose monitor, because they could be used to

1 guide treatment decisions “such as changing one’s diet or insulin dosage based
2 solely on the readings of the CGM.” *Id.* at 7. These highly accurate CGMs are
3 covered as durable medical equipment under the terms of the CMS Ruling, *id.* at 8,
4 but less accurate devices are not, *id.* at 15.

5 **B. Medicare Coverage Determination and Claim Appeal Process**

6 To seek reimbursement for the cost of a continuous glucose monitor or
7 anything else, “a Medicare Part B beneficiary must submit a claim for an ‘initial
8 determination’ of whether ‘the items and services are covered or otherwise
9 reimbursable.’” *Porzecanski v. Azar*, 943 F.3d 472, 475–76 (D.C. Cir. 2019)
10 (quoting 42 C.F.R. § 405.920); *see* 42 U.S.C. § 1395ff(a)(1). “Initial coverage
11 determinations are made by” Medicare administrative contractors hired by the
12 agency “to manage the preliminary claims administration process.” *Porzecanski*,
13 943 F.3d at 476. “If the contractor denies the beneficiary’s claim,” he may “obtain
14 a ‘redetermination’ from the same contractor.” *Id.* (citing 42 U.S.C.
15 § 1395ff(a)(3)(A); 42 C.F.R. § 405.940). “If unsuccessful, the beneficiary can
16 seek ‘reconsideration’ by a ‘qualified independent contractor’ who is wholly
17 independent of the initial determination contractor.” *Id.* (citing 42 U.S.C.
18 § 1395ff(c)(1)–(2); 42 C.F.R. § 405.960).

19 If the beneficiary remains unsatisfied, subject to a minimum amount-in-
20 controversy requirement, “he can request a hearing before an administrative law

1 judge (ALJ).” *Id.* (citing 42 C.F.R. § 405.1000); *see* 42 U.S.C. § 1395ff(b)(1)(E).
2 After that, he can seek review by the Medicare Appeals Council, *see* 42 C.F.R.
3 § 405.1100, which makes the final decision for the Secretary, *id.* § 405.1130. If
4 the beneficiary is not satisfied with the decision of the Council, he may then seek
5 judicial review within 60 days, 42 U.S.C. § 405(g), subject to another amount-in-
6 controversy requirement, *id.* § 1395ff(b)(1)(E).

7 **C. Procedural Background**

8 Jeremy Olsen sought reimbursement by Medicare Part B for a continuous
9 glucose monitor transmitter and sensors that he received in 2018. The initial
10 determination and redetermination were unfavorable, AR 150, 160–61, 163, as was
11 the decision on reconsideration, AR 124. Mr. Olsen sought review by an
12 administrative law judge, who found his continuous glucose monitor to be a
13 covered device. AR 40–43.

14 The Medicare Appeals Council undertook review on its own motion. AR
15 29. The Appeals Council found that CMS Ruling 1682-R required it to deny
16 coverage. AR 12–22. Mr. Olsen sought timely judicial review, and venue was
17 transferred to this district.

ARGUMENT

A. The Appeals Council's decision was substantively valid.

Following CMS Ruling 1682-R, the Medicare Appeals Council determined that Mr. Olsen's continuous glucose monitor was not sufficiently accurate to be covered as durable medical equipment under Medicare Part B. Under the terms of that Ruling, CGMs are only covered if they are accurate enough to be "used for making diabetes treatment decisions, such as changing one's diet or insulin dosage based solely on the readings of the CGM." CMS Ruling 1682-R at 7. Less accurate CGMs are not covered. This determination is neither arbitrary, contrary to statute, nor "non-sensical" (as Plaintiff would have it, *see* Mot. at 3).

To begin with, it is not contrary to statute because a continuous glucose monitor is not a "blood glucose monitor," which the Medicare statute defines as durable medical equipment. 42 U.S.C. § 1395x(n). As CMS Ruling 1682-R explains, CGMs measure glucose levels in the interstitial fluid between patients' cells, not in their blood. CMS Ruling 1682-R at 6. Congress has determined that "blood-testing strips and blood glucose monitors for individuals with diabetes" should be covered as durable medical equipment. 42 U.S.C. § 1395x(n). "[B]lood-testing strips" are the supplies for a patient's "blood glucose monitor," a device that monitors glucose levels in the patient's blood. Continuous glucose monitors simply do not do so. Instead, they measure something correlated with the

1 level of glucose in a patient’s blood (that is, the level of glucose in their interstitial
2 fluid). To the extent that there is any ambiguity in the statutory phrase, the
3 Secretary’s interpretation—that blood glucose monitors must monitor blood
4 glucose levels, not the levels of glucose in other bodily fluids, even if they are
5 correlated to blood glucose levels—is plainly reasonable and therefore entitled to
6 this Court’s deference. *Chevron U.S.A., Inc. v. Natural Res. Def. Council*, 467
7 U.S. 837, 843 (1984).

8 Nor was it arbitrary or otherwise unlawful for the Secretary to distinguish
9 between continuous glucose monitors that are accurate enough to be “used for
10 making diabetes treatment decisions, such as changing one’s diet or insulin dosage
11 based solely on the readings of the CGM,” which are covered under the terms of
12 CMS Ruling 1682-R (at 7), and less accurate devices, which are not covered. The
13 Secretary’s position is that continuous glucose monitors are only covered as
14 durable medical equipment by Medicare Part B if they are accurate enough to
15 guide treatment decisions. *Id.* at 8. Less accurate devices, whose readings must be
16 confirmed by using a blood glucose monitor, are not covered. *Id.* at 15. This is not
17 an arbitrary distinction. There are more accurate and less accurate CGMs on the
18 market, and it is entirely reasonable for the Secretary to encourage the use of the
19 more accurate devices. Although this might well have been accomplished through
20 the establishment of quality standards under 42 U.S.C. § 1395m(a)(20), the

1 Secretary has instead drawn this reasonable distinction through an interpretation of
2 the Medicare statute and its implementing regulations.

3 The Secretary's view has been that the "medical purpose" of a CGM is to
4 enable a beneficiary to make treatment decisions, and that less-accurate CGMs do
5 not serve that medical purpose. *See* CMS Ruling 1682-R at 9 ("The medically
6 necessary function of a glucose monitor is to inform the patient about their glucose
7 level so that they can make diabetes treatment decisions such as changing their diet
8 or insulin dosage."). The Secretary has sometimes described the less-accurate
9 devices that do not serve this medical purpose as "adjunctive" or "precautionary."
10 *See* CMS Ruling 1682-R at 6–7, 14. But the core of the Secretary's position has
11 been that certain CGMs do not effectively serve the medical purpose of that
12 device. CMS Ruling 1682-R sets out a coverage standard under which more
13 accurate CGMs are covered, and less accurate CGMs are not. That determination
14 is reasonable, lawful, and entitled to deference from this Court.

15 Nonetheless, the Secretary is currently reconsidering his position on whether
16 devices such as the continuous glucose monitor at issue here should be considered
17 durable medical equipment within the meaning of the Medicare statute and
18 regulations. He recently published a notice of proposed rulemaking which would,
19 if finalized, "classify CGM systems . . . as DME" whether or not they can be used
20 to make treatment decisions on the basis of their readings alone. 85 Fed. Reg.

1 70,358, 70,403–04 (Nov. 4, 2020). The comment period closes on January 4,
2 2021; the Secretary will apprise the Court if and when a rule is finalized.

3 **B. The procedural claim should be dismissed, has been waived, and**
4 **could not lead to the only relief sought here.**

5 Plaintiff suggests that CMS Ruling 1682-R was issued in violation of the
6 Medicare statute’s notice-and-comment requirement, *see* 42 U.S.C.
7 § 1395hh(a)(2), and that the decision of the Appeals Council was therefore tainted
8 by its reliance on a procedurally invalid CMS Ruling. In doing so, Plaintiff
9 appears to press his claim under 5 U.S.C. § 706(2)(D), which should be dismissed
10 for the reasons set forth in the Secretary’s pending motion to dismiss.

11 Moreover, as another district court has recently held, an objection to the
12 procedural validity of CMS Ruling 1682-R is waived if it is not raised before the
13 Appeals Council, which it was not here. *Zieroth v. Azar*, 2020 WL 5642614, at *3
14 (N.D. Cal. Sept. 22, 2020) (“[T]he Court finds the procedural challenge [to CMS
15 Ruling 1682-R] asserted by Zieroth was waived” when it was not raised before the
16 agency.). *See Lands Council v. McNair*, 629 F.3d 1070, 1076 (9th Cir. 2010) (“A
17 party forfeits arguments that are not raised during the administrative process.”).

18 And even if the Court determines that this procedural claim should not be
19 dismissed and was not waived, the Court need not reach it unless the Court first
20 upholds the substantive validity of the Secretary’s decision. The procedural

1 argument is a fallback position that would not lead to the principal relief that
2 plaintiff is seeking: an order that the Secretary approve Mr. Olsen's claim for
3 benefits. If the Secretary's final decision improperly relied on a procedurally
4 invalid CMS Ruling, then the remedy is a remand so that the Secretary can decide
5 Mr. Olsen's claim without reference to the disputed Ruling. *See Allina Health*
6 *Servs. v. Sebelius*, 746 F.3d 1102, 1111 (D.C. Cir. 2014) (citing *Sec. & Exch.*
7 *Comm'n v. Chenery Corp.*, 332 U.S. 194, 201 (1947) ("After the remand was
8 made, therefore, the Commission was bound to deal with the problem afresh,
9 performing the function delegated to it by Congress.")). Because a procedural
10 error would not give this Court license to make a *de novo* coverage determination
11 itself, any procedural failing in the decision of the Medicare Appeals Council
12 should not lead to a substantive reversal of the Secretary's coverage determination.

13 CONCLUSION

14 The Court should uphold the decision of the Medicare Appeals Council,
15 enter summary judgment in favor of the Secretary, and deny Plaintiff's motion for
16 summary judgment.

Respectfully submitted,

JEFFREY BOSSERT CLARK
Assistant Attorney General

MICHELLE BENNETT
Assistant Director, Federal Programs Branch

/s/ James Bickford

JAMES BICKFORD

Trial Attorney (N.Y. Bar No. 5163498)

United States Department of Justice

Civil Division, Federal Programs Branch

1100 L Street, NW

Washington, DC 20530

James.Bickford@usdoj.gov

Telephone: (202) 305-7632

Facsimile: (202) 616-8470

Counsel for Defendant

Date: December 9, 2020